Resumen
La neuromielítis óptica o Enfermedad de Devic es un síndrome desmielinizante severo que a pesar de su baja incidencia, presenta un reto diagnóstico y terapéutico, principalmente en su diferenciación con esclerosis múltiple. Con el descubrimiento de la asociación de los anticuerpos contra canales de acuaporina 4 en la fisiopatología de este síndrome se han ampliado las herramientas para establecer un diagnóstico con mayor certeza y definir las posibilidades de tratamiento. A continuación se presenta una actualización de la literatura respecto al papel de los anticuerpos antiacuaporinas 4 en el diagnóstico y tratamiento de la neuromielítis óptica.
Citas
SELLNER J, BOGGILD M, CLANET M ET AL. EFNS guidelines on diagnosis and management of neuromyelitis Optica. European Journal of Neurology 2010;17:1019-1032.
WINGERCHUK DM, HOGANCAMP WF, O_BRIEN PC, ET AL. The clinical course of neuromy-elitis optica (Devic_s syndrome). Neurology 1999;53:1107-1114.
LANA-PEIXOTO M. Devic's neuromyelitis optica. Arq Neuropsiquiatr 2008;66:120-138.
GRABER DJ, LEVY M, KERR D, ET AL. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 2008;5:22-80.
TAIT MJ, SAADOUN S, BELL BA, ET AL. Water movements in the brain:role of aquaporins. Trends Neurosci 2008;31:37-43.
NAGGELHUS EA, HORIO Y, INANOBE A, ET AL. Immunogold evidence suggests that coupling of K+ siphoning and water transport in rat retinal Müller cells is mediated by a coenrichment of Kir4.1 and AQP4 in specific membrane domains. Glia 1999;26:47-54.
ZENG XN, SUN XL, GAO L, FAN Y, DING JH, HU G. Aquaporin-4 deficien-cy down-regulates glutamate uptake and GLT-1 expression in astrocytes. Mol Cell Neurosci 2007;34:34-39.
BENARROCH EE. Aquaporin-4, homeostasis, and neurologic disease. Neurology 2007;69:2266-2268.
GRIESDALE DE, HONEY CR. Aquaporins and brain edema. Surg Neurol 2004;61:34-39.
MERLE H, OLINDO S, BONNAN M, ET AL. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007;114:810-815.
WINGERCHUK DM, WEINSHENKER BG. Neuromyelitis optica:clinical predictors of a relapsing course and survival. Neurology 2003;60:848-853.
MANDLER RN, DAVIS LE, JEFFERY DR, ET AL. Devic_s neuromyelitis optica:a clinicopathologi-cal study of 8 patients. Ann Neurol 1993;34:162-168.
FARDET L, GENEREAU T, MIKAELOFF Y, ET AL. Devic_s neuromyelitis optica:study of nine cases. Acta NeurolScand 2003;108:193-200.
ORIORDAN JI, GALLAGHER HL, THOMPSON AJ, ET AL. Clinical, CSF, and MRI findings in Devic_s neuromielitis optica. J Neurol Neurosurg Psychiatry 1996;60:382-387.
POPPE AY, LAPIERRE Y, MELANCON D, ET AL. Neuromyelitis optica with hypothalamic involvement. Mult Sckr 2005;11:617-621.
VERNANT JC, CABRE P, SMADJA D, ET AL. Recurrent optic neuromyelitis with endocrinopathies:a new syndrome. Neurology 1997;48:58-64.
SEZE J, STOJKOVIC T, FERRIBY D, ET AL. Devic_s neuromyelitis optica:clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002;197:57-61.
CABRERA-GOMEZ JA, KURTZKE JF, GON-ZALEZ-QUEVEDO A, ET AL. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009;256:35-44.
KANZAKI M, MOCHIZUKI H, OGAWA G, ET AL. Clinical features of opticospinal multiple sclerosis with anti-aquaporin 4 antibody. Eur Neurol 2008;60:37-42.
JOHNSON G, MILLER DH, MACMANUS D, ET AL. STIR sequences in NMR imaging of the optic nerve. Neuroradiology 1987;29:238-245.
KUPERSMITH MJ, ALBAN T, ZEIFFER B, ET AL. Contrastenhanced MRI in acute optic neuritis:relationship to visual performance. Brain 2002;125:812-822.
WINGERCHUK DM, LENNON VA, PITTOCK SJ, ET AL. Revised diagnostic criteria for neuromy-elitis optica. Neurology 2006;66:1485-1489.
FILIPPI M, ROCCA MA, MOIOLA L, ET AL. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic_s neuromyelitis optica. Neurology 1999;53:1705-1710.
PITTOCK SJ, LENNON VA, KRECKE K, ET AL. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-396.
FAZIO R, MALOSIO ML, LAMPASONA V, ET AL. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler 2009;15:1153-1163.
WATERS P, VINCENT A. Detection of antiaquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008;15:99-105.
CABRE P, GONZALEZ-QUEVEDO A, BONNAN M, ET AL. Relapsing neuromyelitis optica:long term history and predictors of death. J Neurol Neurosurg Psychiatry 2009;80:1162-1164.
PAPAIS-ALVARENGA RM, MIRANDA-SANTOS CM, PUCCIONI-SOHLER M, ET AL. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neu-rosurg Psychiatry 2002;73:429-435.
WEINSHENKER BG, WINGERCHUK DM, VUKUSIC S, ET AL. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-569.
DE SE-ZE J, ARNDT C, JEANJEAN L, ET AL. Relapsing inflammatory optic neuritis:is it neuromyelitis optica?. Neurology 2008;70:2075-2076.
MARIGNIER R, DE SEZE J, VUKUSIC S, ET AL. NMO-IgG and Devic_s neuromyelitis optica:a French experience. Mult Scler 2008;14:440-445.
JARIUS S, ABOUL-ENEIN F, WATERS P, ET AL. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-3080.
LALIVE PH, MENGE T, BARMAN I, CREE BA, GENAIN CP. Identification of new serum autoantibodies in neuromyelitis optica using protein microar-rays. Neurology 2006;67:176-177.
MARIGNIER R, GIRAUDON P, VUKUSIC S, CONFAVREUX C, HONNORAT J. Anti-aquapo-rin-4 antibodies in Devic's neuromyelitis optica:therapeutic implications. Ther Adv Neurol Disord 2010;3:311-321.
MATIELLO M, LENNON VA, JACOB A, ET AL. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-2200.
WEINSHENKER BG, WINGERCHUK DM, VUKUSIC S, ET AL. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-569.
PITTOCK SJ, LENNON VA, DE SEZE J, ET AL. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
MCKEON A, LENNON VA, JACOB A, ET AL. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39: 87-90.
KIRA J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci 2008;1142:58-71.
MILLER DH, WEINSHENKER BG, FILIPPI M, ET AL. Differential diagnosis of suspected multiple sclerosis:a consensus approach. Mult Scler 2008;14:1157-1174.
LLUFRIU S, CASTILLO J, BLANCO Y, ET AL. Plasma exchange for acute attacks of CNS demy-elination:predictors of improvement at 6 months. Neurology 2009;73:949-953.
WEINSHENKER BG, OBRIEN PC, PETTER-SON TM, ET AL. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-886.
KEEGAN M, PINEDA AA, MCCLELLAND RL, ET AL. Plasma exchange for severe attacks of CNS demyelination:predictors of response. Neurology 2002;58:143- 146.
WATANABE S, NAKASHIMA I, MISU T, ET AL. Therapeutic efficacy of plasma exchange In NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-132.
RUPRECHT K, KLINKER E, DINTELMANN T, ET AL. Plasma exchange for severe optic neuritis:treatment of 10 patients. Neurology 2004;63:1081-1083.
BONNAN M, VALENTINO R, OLINDO S, ET AL. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009;15:487-492.
MIYAMOTO K, KUSUNOKI S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 2009; 13: 505-508.
MANDLER RN, AHMED W, DENCOFF JE. Devic_s neuromyelitis optica:a prospective study of seven patients treated with prednisone and azathio-prine. Neurology 1998;51:1219-1220.
BICHUETTI DB, LOBATO DE OLIVEIRA EM, OLIVEIRA DM, AMORIN DE SOUZA N, GABBAI AA. Neuromyelitis Optica Treatment:Analysis of 36 Patients. Arch Neurol 2010;67:1131-1136.
WINGERCHUK DM, WEINSHENKER BG. Neuromyelitis optica. Curr Treat Options Neurol 2005;7:173-182.
JACOB A, WEINSHENKER BG, VIOLICH I, ET AL. Treatment of neuromyelitis optica with rituximab:retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448.
CREE BA, LAMB S, MORGAN K, ET AL. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-1272.
KIMBY E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-473.
MOK CC, TO CH, MAK A, ET AL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 2008;35:172-174.
WEINSTOCK-GUTTMAN B, RAMANATHAN M, LINCOFF N, ET AL. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-963.
JACOB A, MATIELLO M, WEINSHENKER BG, ET AL. Treatment of neuromyelitis optica with mycophenolate mofetil:retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-1133.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.